

Navigating Pregnancy Testing in Chronic Pain Management for Women of Reproductive Age

Shoran Tamura¹, Swarnima Vardhan², Kathryn Breidenbach³, Naum Shaparin³,
Amaresh Vydyanathan³, Karina Gritsenko³

¹Department of Anesthesiology, Columbia University, New York, NY, USA; ²Department of Anesthesiology, Yale New Haven Health/Bridgeport Hospital, Bridgeport, CT, USA; ³Department of Anesthesiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA

Correspondence: Karina Gritsenko, Email kgritsen@montefiore.org

Background: Women of childbearing age often require a nuanced and individualized approach to chronic pain management, especially when pregnancy is a possibility. Interventional procedures involving ionizing radiation, such as fluoroscopy-guided injections, raise specific concerns for fetal safety, including risks of embryo death, congenital anomalies, intellectual disability, and microcephaly. Despite national recommendations from organizations like the American College of Radiology (ACR), implementation of pregnancy screening in the pain management context remains limited.

Methods: This review synthesizes current literature and practice guidelines to assess the gaps in pregnancy screening protocols within chronic pain management settings. It highlights challenges in evaluating pregnancy status before initiating pharmacologic or fluoroscopic procedures, and it examines both biological testing limitations and procedural risks.

Results: Fluoroscopically guided procedures may exceed the teratogenic radiation threshold of 50 mGy, underscoring the critical need for reliable pregnancy screening. While urine and serum hCG tests are widely used, both are susceptible to false negatives and positives due to timing, hormone variants, and analytical interferences. Integrating clinical evaluation with menstrual history, point-of-care testing, and serum confirmation may improve diagnostic accuracy and ensure greater protection for the fetus.

Conclusion and Recommendations: To address safety concerns, this review proposes a structured pregnancy screening algorithm tailored for chronic pain practices. Key recommendations include: routine screening of all reproductive-age women prior to procedures involving radiation or teratogenic medications, use of serum hCG testing when uncertainty exists, optimizing radiation exposure strategies, and clear, informed consent processes outlining fetal risks. Adoption of these best practices may improve clinical consistency and enhance patient safety.

Keywords: pregnancy, chronic pain, radiation, medications, interventions

Introduction

Chronic pain is a major public health issue in the United States, affecting roughly one in five adults as of 2021. This widespread burden carries significant consequences—including increased healthcare costs, lost productivity, and a higher risk of depression, dementia, suicidal ideation, and substance abuse.¹ Among those most affected are women of childbearing age, many of whom experience chronic low back and neck pain—conditions that accounted for \$134.5 billion in medical spending in 2016 alone.^{2,3}

Women tend to experience chronic pain more frequently than men. A global meta-analysis involving 30 studies found that 11.2% of women reported chronic widespread pain, compared to just 7.2% of men.⁴ This disparity is linked to a mix of biological, psychological, and social influences. For women in midlife—often balancing demanding roles at home and at work—chronic pain can severely impact quality of life.⁵

Pain management in women of reproductive age presents a unique challenge. During pregnancy, physiological changes—including increased levels of relaxin, estrogen, and progesterone—can lead to ligament laxity and altered biomechanics. These changes commonly result in lumbopelvic pain, which tends to intensify in the second and third

trimesters.⁶ In addition, some women develop heightened sensitivity to pain, even in the absence of mechanical issues, due to both hormonal shifts and emotional stressors.⁷

Interestingly, pregnancy itself can sometimes blunt pain perception. By the third trimester, many women experience what's known as pregnancy-induced analgesia, a phenomenon driven by hormonal changes and immune modulation through T-cell and opioid pathways.^{8,9} Recent work even points to the involvement of the PD-L1/PD-1 pathway in reducing spinal inflammation and pain perception.⁹ Still, despite this natural modulation of pain, many women require treatment. Studies show that women aged 18–45 represent a significant share of chronic pain clinic patients, accounting for between 25–37% of visits.^{10,11}

When it comes to pain management, especially in this demographic, the opioid crisis has made things even more complicated. The CDC's 2022 guidelines for opioid prescribing underscore the importance of avoiding opioids when possible—particularly for pregnant patients—and instead encourage non-opioid medications and non-pharmacologic strategies.¹²

However, what has not yet been fully assessed in chronic pain management is pregnancy screening—especially when interventional procedures like fluoroscopy are involved as many such procedures carry risks for a developing fetus.

The American Society of Anesthesiologists (ASA) recommends considering pregnancy testing for women of childbearing age with uncertain or suggestive pregnancy histories, particularly when fluoroscopy is planned.¹³ This aligns with the American College of Radiology (ACR) guidance, advising pregnancy testing within 72 hours prior to fluoroscopic procedures likely to deliver doses above 100 mGy.¹⁴ Similarly, the American Society for Gastrointestinal Endoscopy (ASGE) advocates confirming pregnancy status before procedures involving ionizing radiation, particularly during early gestation, to mitigate potential fetal risks.¹⁵ Still, these recommendations are often general, and pain clinics vary widely in how they implement them.

Our review focuses specifically on this gap: the unclear approach to pregnancy screening specifically in chronic pain management. We propose a more standardized approach—one that considers what kind of testing is appropriate and when those tests should be performed. By doing so, we aim to help practitioners balance effective pain care with the safety of potential pregnancies.

Methods

The literature review was conducted using PubMed and OpenEvidence. Data was collected by linking different variations of the keywords together such as pregnancy, pregnancy testing, chronic pain management, radiation, medications, interventions, guidelines. For example, “Pregnancy testing guidelines in chronic pain management”. Inclusion criteria included English language and peer-reviewed articles. Exclusion criteria included articles focusing solely on non-clinical populations or animal models. There were no established time frame restrictions for the literature search.

Management of Chronic Pain in Women of Childbearing Age

Non-Pharmacological Strategies

For women who are pregnant or may become pregnant, non-pharmacological pain treatments are often the safest starting point. These treatments provide relief with minimal side effects and are considered safe in pregnancy.¹⁶

For pregnancy-related low back pain, interventions like progressive muscle relaxation, Kinesio Taping, and transcutaneous electrical nerve stimulation (TENS) have been shown to reduce discomfort and improve mobility.¹⁷ Likewise, some patients with chronic pain have favorable responses to multimodal therapies such as pelvic floor physical therapy, acupuncture, psychotherapy, and neuromodulation.

Exercise-based interventions also show strong evidence for improving pregnancy-related musculoskeletal pain.¹⁸ Complementary therapies—such as chiropractic care, craniosacral therapy, and osteomanipulative techniques—may offer additional benefit when used under the guidance of experienced providers.¹⁹

Because these non-pharmacological approaches are considered safe in pregnancy, pregnancy testing is usually not necessary. Though, while these interventions reduce reliance on medications, they may not eliminate the need for them altogether, in which case pregnancy testing is likely warranted.

Pharmacological Strategies

Acetaminophen remains the first-line option due to its strong safety profile across all trimesters.^{20,21} However, like any medication, it should be used at the lowest effective dose and for the shortest duration necessary.

NSAIDs are generally safe during early pregnancy but are typically avoided in the third trimester due to the risk of fetal complications, including premature ductus arteriosus closure and renal impairment.^{20,21}

Opioids, while sometimes required for severe pain, present complex risks. A 2024 systematic review and a 2022 meta-analysis present mixed findings on the teratogenic risks of opioids. While some studies suggest elevated risks for specific birth defects—such as cleft palate or gastrointestinal malformations—others report no significant associations with first-trimester exposure or short-term use.^{22,23} To err on the side of caution, guidelines recommend limiting opioids to short-term use when absolutely necessary—and only after non-opioid alternatives have been exhausted.¹²

Other medications like gabapentinoids and tricyclic antidepressants may be cautiously considered for chronic pain during pregnancy, but safety data remain limited. These agents are typically reserved for short-term use when safer options have failed.²⁰ The uncertainty of teratogenic effects of both opioids and other medications underscores the importance of pregnancy screening before initiating opioid therapy in women of reproductive age.

Radiation Exposure and Pregnancy Risk

When non-pharmacological and pharmacological measures have failed, interventional pain procedures may be warranted. For women undergoing these procedures, radiation exposure introduces another layer of complexity. Fluoroscopy-guided injections can expose a developing fetus to ionizing radiation. Radiation risks are typically categorized as deterministic (eg, malformations, growth restriction) and stochastic (eg, childhood cancer, genetic mutations). The likelihood and severity of these outcomes depend on both the dose and the timing of exposure.²⁴

- Below 50 mGy, fetal risk is considered negligible.
- Between 50–100 mGy, risk is unclear and varies based on gestational age.
- Above 100–150 mGy, the risk of adverse outcomes—including neurological impairments and congenital anomalies—increases significantly.²⁵

Organogenesis, occurring between weeks 2 and 7 of gestation, represents the most vulnerable period for deterministic effects. For this reason, early pregnancy screening is essential when planning fluoroscopic procedures.

Fluoroscopically guided interventions can deliver higher than 50 mGy doses, particularly if multiple views or prolonged imaging are needed. For reference, the International Commission on Radiological Protection (ICRP) notes that most *diagnostic* imaging procedures fall below the 50 mGy threshold which is not associated with significant risks such as miscarriage, genetic damage, or teratogenicity.^{26,27}

Pregnancy screening is a simple, low-cost safeguard. However, despite the pre-procedure pregnancy testing recommendations from professional societies like the ACR and ACC, there remains a lack of formalized, consistent pregnancy testing protocols specifically tailored to chronic pain management settings.

Pregnancy Testing

Biological Basis of hCG Testing

Pregnancy tests typically rely on detecting intact human chorionic gonadotropin (hCG), a hormone produced shortly after implantation, around 8–10 days post-ovulation.^{28–32} hCG levels rise through the first trimester, peak, and gradually decline by mid-pregnancy.^{30,33} After a pregnancy ends—whether through delivery or miscarriage—levels typically normalize within 4–6 weeks.

hCG exists in multiple forms due to glycosylation apart from intact hCG, including free subunits, and nicked variants.^{34–36} This variability can affect test performance, especially early in gestation.

While clinical history can sometimes exclude pregnancy—such as in patients with hysterectomy or active cancer treatment—most cases require testing to confirm pregnancy status.

Urine Pregnancy Tests

Urine-based hCG tests are widely used due to their convenience and affordability. They offer results within minutes and are reliable once hCG levels exceed 20 mIU/mL.²⁸

Serum Pregnancy Tests

Serum beta-hCG tests are more sensitive and can detect pregnancy earlier. Results below 5 mIU/mL indicate a non-pregnant state; results above 25 mIU/mL confirm pregnancy. Indeterminate values (6–24 mIU/mL) warrant repeat testing after 48 hours.³⁷

Though more accurate, serum testing takes longer and may not be feasible in urgent scenarios. It is especially important in high-risk populations or when urine tests are incongruent with clinical signs.¹⁴

However, these tests may yield false negatives or false positives in specific clinical contexts.

False Negatives

While pregnancy testing is accessible and effective, clinicians must recognize its limitations and the potential for diagnostic errors. The most common cause of false-negative results is early testing, before hCG levels rise above the detection threshold.^{38,39} Variations in ovulation, fertilization, implantation, or delayed menses can all contribute to this.

Another cause is the hook effect, where extremely high hCG levels (eg, in gestational trophoblastic disease) oversaturate the test, leading to a falsely negative result.^{40–42} A related issue, the variant hook effect, occurs when specific hCG isoforms (eg, free beta-subunit) interfere with test accuracy, especially between 7–12 weeks of gestation, leading to false-negative urine results.⁴¹ The presence of these variants can lead to significant discrepancies in hCG measurements, which are critical for diagnosing and monitoring pregnancy-related conditions. Therefore, it may be essential to choose immunoassays that can accurately detect and differentiate between the various forms of hCG, including the free beta-subunit, to avoid diagnostic errors caused by these effects.

False Positives

False-positive pregnancy test results can arise in a variety of clinical scenarios. One common situation involves biochemical pregnancies, such as those occurring after miscarriage, abortion, or delivery, where human chorionic gonadotropin (hCG) remains detectable in the bloodstream before it has fully cleared.³⁴ Another cause is the use of exogenous hCG in fertility treatments or performance-enhancing doping, with the hormone remaining traceable for up to two weeks after injection.⁴³ Certain tumors can also secrete hCG, leading to elevated levels in individuals who are not pregnant.⁴⁴ In perimenopausal or postmenopausal women, the pituitary gland may produce hCG, contributing to false-positive results in this population.⁴³ Test interference is another consideration—high doses of biotin, for example, can distort serum-based assay results, although this typically does not affect urine tests, which remain negative in such cases.⁴⁵ Lastly, familial hCG syndrome, a rare inherited condition, can lead to persistently elevated hCG levels, creating a clinical picture that mimics pregnancy despite the absence of gestation.⁴⁶

A false negative may expose a fetus to teratogenic interventions, while a false positive could prevent a patient from receiving potentially beneficial therapies due to fetal risk. Pregnancy testing is a critical tool for early pregnancy detection, but given the above limitations clinicians must interpret results with a nuanced understanding of timing and hormone dynamics.

Recommendations for Best Practices

This paper focuses on refining pregnancy screening in chronic pain management. While general safety protocols exist, this review tailors specifically to the chronic pain population, where medication use and ionizing radiation is common. In women of childbearing age who may be candidates for certain pain medications or interventional procedures, consider the following:

Pregnancy Screening

All females of reproductive age should be screened using a standardized questionnaire or direct inquiry. Proceed only if:

- The last menstrual period (LMP) was within 7 days, or

- LMP was <4 weeks ago and the patient has had no sexual activity since, or
- LMP >7 days and the patient has had a sterilization procedure like a tubal ligation or hysterectomy.

If these are not met:

- Obtain a POC urine pregnancy test.
- If positive or ambiguous, conduct serum hCG.
- If pregnancy is confirmed, discuss risks, benefits, alternatives ± and obtain informed consent for fluoroscopy-guided procedure.
- If refusing pregnancy testing, document this clearly in the medical record and obtain informed consent for fluoroscopy-guided procedure.

If there is any doubt about pregnancy status, confirmatory testing with serum hCG should always be performed.

See Pregnancy Screening Flowchart and Questionnaire for Women of Reproductive Age in [Appendices 1](#) and [2](#), respectively.

Informed Consent

Clear, empathetic communication is critical. Risks to both mother and fetus should be explained in understandable language. Explain both deterministic effects (eg, developmental delay from high-dose exposure) and stochastic effects (eg, theoretical cancer risk). Provide printed materials and encourage patient questions. Document patient understanding and consent. (See [Appendix 3](#) for example informed consent).

Optimized Radiation Exposure

In addition to using the lowest effective radiation dose, incorporate strategies to minimize radiation exposure such as Lead shielding over the abdomen and pelvis whenever feasible, Modified imaging protocols that reduce fluoroscopy time and dose rate, Collimation to limit the x-ray beam to the area of interest, Last-image hold and pulsed fluoroscopy to reduce exposure duration, and When appropriate, opt for non-ionizing modalities, such as ultrasound or MRI.

For example, in a retrospective study comparing ultrasound- and fluoroscopy-guided selective nerve root blocks for lumbar radicular pain showed no significant difference in six-month outcomes.⁴⁷ While some systematic reviews favor fluoroscopy for functional outcomes,⁴⁸ MRI and ultrasound remain viable alternatives for minimizing fetal risk.

Exposure After Unknown Pregnancy

Counsel patients about relative fetal risks. If the procedure delivers radiation doses below 50 mGy, reassure them that these levels are not associated with significant risks to the fetus. If the procedure exceeded 50 mGy, or if there is significant patient concern, have them follow-up with their obstetrics provider.

Discussion

This review adds clinical context and a structured pregnancy screening protocol tailored for chronic pain management. By providing screening guidance, this paper closes a critical gap in pregnancy safety protocols.

These tools can be seamlessly integrated into clinical workflows, providing guidance that may inform institutional policy updates and influence national guidelines, including those from interventional pain societies.

To enhance clinical practice and improve patient safety, several actionable recommendations can be implemented. First, integrating the screening algorithm directly into electronic health records (EHRs) can help streamline decision-making and ensure consistent application across clinical settings. Consent forms should also be updated to explicitly include information on both radiation and medication risks, promoting informed decision-making. When feasible and clinically appropriate, ultrasound should be prioritized as the first-line imaging modality due to its safety profile, particularly in reproductive-age patients.

Looking ahead, future research should focus on several key areas. Prospective studies comparing clinical outcomes using different screening protocols will be vital to understanding the real-world effectiveness of current approaches. Additionally, investigating patient understanding and satisfaction regarding counseling on radiation risks will offer insight into communication strategies and informed consent processes. Research should also explore the optimal timing and type of screening in diverse patient populations to ensure equitable and personalized care. Finally, studies comparing the outcomes of algorithm-driven screening protocols versus routine clinical practice could provide valuable evidence to support broader implementation.

Conclusion

With the exception of non-pharmacologic interventions, oftentimes, pharmacologic or interventional procedures involving ionizing radiation necessary in chronic pain management pose unique risks to women who may be pregnant. A thoughtful, patient-centered approach to pregnancy screening can prevent avoidable harm and support better outcomes. Adopting structured screening and consent protocols may improve maternal-fetal outcomes, better risk stratify, and increased clinician confidence in procedural safety. To guide widespread implementation, future research should evaluate the effectiveness of different screening strategies and compare the efficacy of algorithm-driven versus routine screening approaches.

Disclosure

All authors except Dr. Naum Shaparin and Dr. Karina Gritsenko report no disclosures for this work. Dr. Naum Shaparin reports receiving research funding AcelRx Pharmaceuticals, Averitas Pharma and Heron Therapeutics. Dr. Karina Gritsenko reports being a consultant for Pacira Biosciences and Grunenthal Pharmaceuticals.

References

1. Rikard SM, Strahan AE, Schmit KM, GP G Jr. Chronic Pain Among Adults — United States, 2019–2021. *MMWR Morb Mortal Wkly Rep*. 2023;72(15):379–385. doi:10.15585/mmwr.mm7215a1
2. Kazeminasab S, Nejadghaderi SA, Amiri P, et al. Neck pain: global epidemiology, trends and risk factors. *BMC Musculoskelet Disord*. 2022;23:26. doi:10.1186/s12891-021-04957-4
3. Zakowski M. How I do it: managing an obstetric patient with chronic pain. *ASRA News*. 2021;46.
4. Andrews P, Steultjens M, Riskowski J. Chronic widespread pain prevalence in the general population: a systematic review. *Eur J Pain*. 2018;22(1):5–18. PMID: 28815801. doi:10.1002/ejp.1090
5. Ref - Pavlović JM, Derby CA. Pain in midlife women: a growing problem in need of further research. *Women's Midlife Health*. 2022;8(1):4. PMID: 35509086; PMCID: PMC9068256. doi:10.1186/s40695-022-00074-x
6. Daneau C, Nougrou F, Abboud J, Ruchat SM, Descarreaux M. Changes in pregnancy-related hormones, neuromechanical adaptations and clinical pain status throughout pregnancy: a prospective cohort study. *PLoS One*. 2025;20(2):e0314158. doi:10.1371/journal.pone.0314158
7. Palsson TS, Beales D, Slater H, O'Sullivan P, Graven-Nielsen T. Pregnancy is characterized by widespread deep-tissue hypersensitivity independent of lumbopelvic pain intensity, a facilitated response to manual orthopedic tests, and poorer self-reported health. *J Pain*. 2015;16(3):270–282. doi:10.1016/j.jpain.2014.12.002
8. Rosen SF, Ham B, Drouin S, et al. T-cell mediation of pregnancy analgesia affecting chronic pain in mice. *J Neurosci*. 2017;37(41):9819–9827. doi:10.1523/JNEUROSCI.2053-17.2017
9. Tan H, Ding Z, Zhang C, Yan J, Yang Y, Li P. The programmed cell death ligand-1/programmed cell death-1 pathway mediates pregnancy-induced analgesia via regulating spinal inflammatory cytokines. *Anesth Analg*. 2021;133(5):1321–1330. doi:10.1213/ANE.0000000000005737
10. Lakha SF, Deshpande A, Assimakopoulos D, Mailis A. Demographics, pain characteristics and diagnostic classification profile of chronic non-cancer pain patients attending a Canadian university-affiliated community pain clinic. *Pain Ther*. 2021;10(2):1413–1426. doi:10.1007/s40122-021-00301-9
11. Mailis-Gagnon A, Yegneswaran B, Lakha SF, et al. Pain characteristics and demographics of patients attending a university-affiliated pain clinic in Toronto, Ontario. *Pain Res Manag*. 2007;12(2):93–99. doi:10.1155/2007/658762
12. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain—United States, 2022. *MMWR Recomm Rep*. 2022;71(3):1–95. doi:10.15585/mmwr.r7103a1
13. Pasha SF, Acosta R, Chandrasekhara V, ASGE Standards of Practice Committee, et al. Routine laboratory testing before endoscopic procedures. *Gastrointest Endosc*. 2014;80(1):28–33. doi:10.1016/j.gie.2014.01.019
14. Hirshfeld JW, Ferrari VA, Ferrari VA, Writing Committee Members, et al. 2018 ACC/HRS/NASCI/SCAI/SCCT expert consensus document on optimal use of ionizing radiation in cardiovascular imaging: best practices for safety and effectiveness. *Catheter Cardiovasc Interv*. 2018;92(2):E35–E97. doi:10.1002/ccd.27659
15. Kwok K, Hasan N, Duloy A, Murad F, Nieto J, Day LW. American society for gastrointestinal endoscopy radiation and fluoroscopy safety in GI endoscopy. *Gastrointest Endosc*. 2021;94(4):685–697.e4. doi:10.1016/j.gie.2021.05.042
16. Wang X, Ding N, Sun Y, et al. Non-pharmacological therapies for treating chronic pelvic pain in women: a review. *Medicine*. 2022;101(49):e31932. doi:10.1097/MD.00000000000031932

17. Chen L, Ferreira ML, Beckenkamp PR, Caputo EL, Feng S, Ferreira PH. Comparative efficacy and safety of conservative care for pregnancy-related low back pain: a systematic review and network meta-analysis. *Phys Ther*. 2021;101(2):pzaa200. doi:10.1093/ptj/pzaa200
18. Liddle SD, Pennick V. Interventions for preventing and treating low-back and pelvic pain during pregnancy. *Cochrane Database Syst Rev*. 2015;2015(9):CD001139. doi:10.1002/14651858.CD001139.pub4
19. Weis CA, Pohlman K, Draper C, daSilva-Oolup S, Stuber K, Hawk C. Chiropractic care for adults with pregnancy-related low back, pelvic girdle pain, or combination pain: a systematic review. *J Manipulative Physiol Ther*. 2020;43(7):714–731. doi:10.1016/j.jmpt.2020.05.005
20. Black E, Khor KE, Kennedy D, et al. Medication use and pain management in pregnancy: a critical review. *Pain Pract*. 2019;19(8):875–899. doi:10.1111/papr.12814
21. Nunge RA, Kendle AM, Alwan S. Pain medication use during pregnancy. *Semin Perinatol*. 2025. doi:10.1016/j.semperi.2025.152074
22. Varney B, Brett J, Zoega H, et al. Opioid analgesic exposure during the first trimester of pregnancy and the risk of major congenital malformations in infants: a systematic review and meta-analysis†. *Anaesthesia*. 2024;79(9):967–977. doi:10.1111/anae.16307
23. Wang X, Wang Y, Tang B, Feng X. Opioid exposure during pregnancy and the risk of congenital malformation: a meta-analysis of cohort studies. *BMC Pregnancy Childbirth*. 2022;22(1):401. doi:10.1186/s12884-022-04733-9
24. Moon EK, Wang W, Newman JS, Bayona-molano mdel P. Challenges in interventional radiology: the pregnant patient. *Semin Intervent Radiol*. 2013;30(4):394–402. PMID: 24436567; PMCID: PMC3835597. doi:10.1055/s-0033-1359734
25. Thabet A, Kalva SP, Liu B, Mueller PR, Lee SI. Interventional radiology in pregnancy complications: indications, technique, and methods for minimizing radiation exposure. *Radiographics*. 2012;32(1):255–274. doi:10.1148/rg.321115064
26. McCollough CH, Schueler BA, Atwell TD, et al. Radiation exposure and pregnancy: when should we be concerned? *Radiographics*. 2007;27(4):909–918. doi:10.1148/rg.274065149
27. Lowe SA. Ionizing radiation for maternal medical indications. *Prenat Diagn*. 2020;40(9):1150–1155. doi:10.1002/pd.5592
28. Betz D, Fane K. Human Chorionic Gonadotropin. In: *StatPearls [Internet]*. Treasure Island (FL): StatPearls Publishing; 2024. Available from <https://www.ncbi.nlm.nih.gov/books/NBK532950>.
29. Wilcox AJ, Baird DD, Weinberg CR. Time of implantation of the conceptus and loss of pregnancy. *N Engl J Med*. 1999;340(23):1796–1799. doi:10.1056/NEJM199906103402304
30. Braunstein GD, Rasor J, Danzer H, Adler D, Wade ME. Serum human chorionic gonadotropin levels throughout normal pregnancy. *Am J Obstet Gynecol*. 1976;126(6):678–681. doi:10.1016/0002-9378(76)90518-4
31. Lenton EA, Neal LM, Sulaiman R. Plasma concentrations of human chorionic gonadotropin from the time of implantation until the second week of pregnancy. *Fertil Steril*. 1982;37(6):773–778. doi:10.1016/S0015-0282(16)46337-5
32. Lenton EA, Hooper M, King H, et al. Normal and abnormal implantation in spontaneous in-vivo and in-vitro human pregnancies. *J Reprod Fertil*. 1991;92(2):555–565. doi:10.1530/jrf.0.0920555
33. Korhonen J, Alfthan H, Ylöstalo P, Veldhuis J, Stenman UH. Disappearance of human chorionic gonadotropin and its alpha- and beta-subunits after term pregnancy. *Clin Chem*. 1997;43(11):2155–2163. doi:10.1093/clinchem/43.11.2155
34. Haenel AF, Hugentobler W, Brunner S. Der postpartale HCG-Titer-Verlauf im mütterlichen Blut und seine klinische Relevanz [The postpartum course of the HCG titer of maternal blood and its clinical relevance]. *Z Geburtshilfe Perinatol*. 1986;190(6):275–278.
35. Lustbader JW, Lobel L, Wu H, Elliott MM. Structural and molecular studies of human chorionic gonadotropin and its receptor. *Recent Prog Horm Res*. 1998;53:395–424.
36. Fournier T. Human chorionic gonadotropin: different glycoforms and biological activity depending on its source of production. *Ann Endocrinol*. 2016;77(2):75–81. doi:10.1016/j.ando.2016.04.012
37. American Pregnancy Association. What is HCG? American pregnancy association; 2022. Available from: <https://americanpregnancy.org/getting-pregnant/hcg-levels/>. Accessed October 22, 2023.
38. Wilcox AJ, Baird DD, Dunson D, et al. Natural limits of pregnancy testing in relation to the expected menstrual period. *JAMA*. 2001;286(14):1759–1761. doi:10.1001/jama.286.14.1759
39. McChesney R, Wilcox AJ, O'Connor JF, et al. Intact HCG, free HCG beta subunit and HCG beta core fragment: longitudinal patterns in urine during early pregnancy. *Hum Reprod*. 2005;20(4):928–935. doi:10.1093/humrep/deh702
40. Gronowski AM, Powers M, Stenman UH, Ashby L, Scott MG. False-negative results from point-of-care qualitative human chorionic gonadotropin (hCG) devices caused by excess hCGbeta core fragment vary with device lot number. *Clin Chem*. 2009;55(10):1885–1886. doi:10.1373/clinchem.2009.133280
41. Gronowski AM, Cervinski M, Stenman UH, Woodworth A, Ashby L, Scott MG. False-negative results in point-of-care qualitative human chorionic gonadotropin (hCG) devices due to excess hCGbeta core fragment. *Clin Chem*. 2009;55(7):1389–1394. doi:10.1373/clinchem.2008.121210
42. Sturgeon CM, McAllister EJ. Analysis of hCG: clinical applications and assay requirements. *Ann Clin Biochem*. 1998;35(Pt 4):460–491. doi:10.1177/000456329803500402
43. Braunstein GD. False-positive serum human chorionic gonadotropin results: causes, characteristics, and recognition. *Am J Obstet Gynecol*. 2002;187(1):217–224. doi:10.1067/mob.2002.124284
44. White S, Harvey R, Mitchell H, Schmid P, Seckl M, Savage P. Characterisation of transient benign hCG elevations in women following chemotherapy for GTT. *J Obstet Gynaecol*. 2011;31(2):169–172. doi:10.3109/01443615.2010.536859
45. Elston MS, Sehgal S, Du Toit S, Yarnley T, Conaglen JV. Factitious graves' disease due to biotin immunoassay interference-a case and review of the literature. *J Clin Endocrinol Metab*. 2016;101(9):3251–3255. doi:10.1210/jc.2016-1971
46. Cole LA. Familial HCG syndrome. *J Reprod Immunol*. 2012;93(1):52–57. doi:10.1016/j.jri.2011.11.001
47. Wang B, Sun Y, Zhang J, et al. Ultrasound-guided versus fluoroscopy-guided lumbar selective nerve root block: a retrospective comparative study. *Sci Rep*. 2024;14:3235. doi:10.1038/s41598-024-53809-3
48. Videman D, Aubakirova M, Aryngazin A, et al. Ultrasound-guided vs. fluoroscopy-guided interventions for back pain management: a systematic review and meta-analysis of randomized controlled trials. *Diagnostics*. 2023;13(22):3474. doi:10.3390/diagnostics13223474

Journal of Pain Research**Publish your work in this journal**

The Journal of Pain Research is an international, peer reviewed, open access, online journal that welcomes laboratory and clinical findings in the fields of pain research and the prevention and management of pain. Original research, reviews, symposium reports, hypothesis formation and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/journal-of-pain-research-journal>

Dovepress
Taylor & Francis Group